Schmidt-Ullrich R K, Wazer D E, DiPetrillo T, Marchant D J, Smith T J, Safaii H, Schmid C, Homer M J
Dept. of Radiation Oncology, New England Medical Center Hospitals, Tufts University School of Medicine, Boston, MA.
Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):545-52. doi: 10.1016/0360-3016(93)90378-9.
Between 1982 and 1988 233 American Joint Committee on Cancer Stage I and II invasive breast carcinomas were prospectively treated in 225 women with conservative tumor excision, careful assessment of histopathological margins, and dose-adjusted irradiation to maximum doses of 70 Gy to the tumor bearing quadrant of the breast.
The pathological stages at presentation were T1N0 and T1N1 in 57% and 13% and T2N0 and T2N1 in 19% and 10% of the patients, respectively. All patients were irradiated according to a policy that, beyond the 50 Gy to the whole breast and draining lymphatics, the tumor-bearing quadrant was boosted in adjustment to the histopathological margin. Normal tissue margins of < 2 mm were considered positive, margins 2-5 mm close, and margins > 5 mm negative and were boosted with 20, 15, and 10 Gy, respectively. Patients in whom the margin could not be assessed were re-excised or boosted to 20 Gy. Re-excisions with no residual carcinoma were not boosted. Most patients boosted to 20 Gy to the tumor-bearing quadrant received interstitial 192-Ir implantations.
The actuarial local control rates in the treated breast were 97.5% at 10 years with three recurrences having occurred at a median of 4.5 years after completion of radiotherapy. An additional two patients failed regionally outside the irradiation portals. The overall and disease-free survival of the whole group is 87.5% and 77%, respectively.
The approach to breast conservation therapy followed in this study has resulted in outstanding local control rates and suggests that there may be a subset of patients that could be irradiated to the tumor bearing quadrant only.
1982年至1988年间,对225例患有I期和II期浸润性乳腺癌的女性患者进行前瞻性治疗,采用保守性肿瘤切除术,仔细评估组织病理学切缘,并对乳房的肿瘤象限进行剂量调整照射,最大剂量达70 Gy。
就诊时的病理分期为T1N0和T1N1的患者分别占57%和13%,T2N0和T2N1的患者分别占19%和10%。所有患者均按照以下策略进行照射:除对全乳和引流淋巴结给予50 Gy照射外,根据组织病理学切缘情况对肿瘤象限进行加量照射。正常组织切缘<2 mm被视为阳性,2 - 5 mm为切缘接近,>5 mm为切缘阴性,分别给予20 Gy、15 Gy和10 Gy的加量照射。切缘无法评估的患者再次切除或加量至20 Gy。再次切除后无残留癌的患者不再加量。大多数肿瘤象限加量至20 Gy的患者接受了组织间192铱植入。
治疗乳房的精算局部控制率在10年时为97.5%,放疗完成后中位4.5年时有3例复发。另外2例患者在照射野之外出现区域复发。全组的总生存率和无病生存率分别为87.5%和77%。
本研究采用的保乳治疗方法取得了出色的局部控制率,提示可能存在一部分患者仅对肿瘤象限进行照射即可。